Agenus (AGEN) is reorganizing its business and operations. The reasons the firm cited comprise sharpening of its focus on clinical development of its two checkpoint inhibitor antibodies and vaccine program. Among others are:

- Closing its Basel site and consolidate key functions to its Cambridge, UK and Lexington, MA facilities,

- Phasing out approximately 50 positions across the organization.

Robert Stein, M.D., Ph.D., President of R&D, will retire to become a senior R&D advisor exclusive to Agenus.

Having built an extraordinary R&D capability for . . .